1 RESEARCH ARTICLE

The effects of physiotherapy programs in COVID-19 patients during
admission in the hospital.

4

Netchanok Jianramas^{1,2}, Veeranoot Nissapatorn³, Chaisith Sivakorn⁴, Maria de Lourdes
Pereira⁵, Anuttra (Chaovavanich) Ratnarathon⁶, Chenpak Salesingh⁷, Eittipad Jaiyen⁷,
Salinee Chaiyakul^{1,2}, Nitita Piya-amornphan^{1,2}, Thanaporn Semphuet^{1,2}, Thanrada
Thiangtham^{1,2}, Kornchanok Boontam^{1,2}, Khomkrip Longlalerng⁰ ^{1,2*}

9

1 Department of Physical Therapy, School of Allied Health Sciences, Walailak University, 10 Nakhon Si Thammarat, Thailand, 2 Movement Science and Exercise Research Center-11 Walailak University (MoveSE-WU), 3 Department of Medical Technology, School of Allied 12 Health Sciences, Walailak University, Nakhon Si Thammarat, Thailand, 4 Intensive Care Unit, 13 University College London Hospitals, London, United Kingdom, 5 CICECO-Aveiro Institute 14 of Materials & Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, 15 Portugal, 6 Pulmonologist, Bamrasnaradura Infectious Disease Institute, Nonthaburi, Thailand, 16 7 Physical Therapy Department, Bamrasnaradura Infectious Disease Institute, Nonthaburi, 17 Thailand 18

- 19 * Corresponding author: <u>klugklig016@gmail.com</u>
- 20

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Data Availability Statement: All relevant data are within the manuscript and its <u>Supporting</u>
 <u>information</u> files.

23 Fundings: The Health Systems Research Institute of Thailand (HSRI-64-184). Project

24 CICECO-Aveiro Institute of Materials, UIDB/50011/2020, UIDP/50011/2020 &

LA/P/0006/2020, financed by national funds through the FCT/MEC (PIDDAC).

26 **Competing interests:** Authors declare no conflict of interest relating to this work.

27

28 Abstract

29 Background and aims

Several recommendations exist regarding the role of physiotherapy programs (PTPs) in COVID-19 patients. However, none of the studies examines the frequency of bedside PTPs during admission. Thus, this study aimed to compare the different bedside PTPs frequencies on the survival rate, length of hospitalization (LoH), referrals to the intensive care unit (ICU), and in-hospital complications. The safety of patients and the physiotherapist was also investigated.

36 Methods

Fifty-two COVID-19 patients were equally assigned into two groups matched on gender and age (1:1 ratio). Experimental group one received 1-2 times of PTPs during hospitalization, and experimental group two received daily PTPs until hospital discharge. The primary outcomes were the survival rate, LoH, referrals to ICU, and in-hospital complications. The secondary outcomes were the adverse events for patients and the number of physiotherapists who contracted with COVID-19.

43

45 **Results**

Most participants were classified as having mild to moderate COVID-19 with a mean age of 45 years. There were no differences between groups in all primary outcome measures (all p > 0.05). The overall survival rate was 98%. One participant from the Ex-G2 group was referred to the ICU. Two Ex-G1 and four Ex-G2 participants had complications. There were no immediate serious adverse events found after PTPs for both groups. None of the physiotherapists tested positive for COVID-19.

52 Conclusion

In COVID-19 patients with mild to moderate conditions, one to two bedside PTPs were enough
to achieve the same results as patients who received daily PTPs. PTPs were safe for COVID19 patients, and physiotherapists.

56 CLINICAL REGISTRATION NUMBER: Thai Clinical Trials, https://www.thaiclinicaltrials.org/,
57 TCTR20210823004.

69 Introduction

70 Since 2019, the human coronavirus disease 2019 (COVID-19) has spread throughout the world, including 71 Thailand [1, 2]. This emerging disease directly affects the patient's respiratory system [3]. Its clinical signs and 72 symptoms range from fever, cough, chill, short, shallow, and difficult breathing, fatigue, malaise, headache, 73 anosmia, ageusia, sore throat, stuffy nose and runny nose, nausea and vomiting, and diarrhea [3-5]. Patients with 74 more severe conditions experience more pronounced signs and symptoms, which are caused by pneumonia [6]. 75 Physiotherapy programs (PTPs) are commonly suggested for adults with pneumonia who are intubated and 76 mechanically ventilated, promoting clearance of secretions and lung compliance [7]. An expert physiotherapist 77 suggested that PTPs should be applied to COVID-19 patients if there is an indication of pneumonia without 78 exudate consolidation, mucous hypersecretion and difficulty clearing secretions, functional decline, and (at risk 79 of) intensive care unit (ICU)-acquired weakness [8-10]. PTPs range from prone positioning, postural drainage, 80 breathing exercises and devices (e.g. positive expiratory pressure and inspiratory muscle training), ventilator settings, positioning, as well as functional training, exercise, and early mobilization [9, 11-13]. 81

82 Notably, suggestions of most experts and some of the studies agreed that patients with severe symptoms or after recovery from the intensive care unit derive benefits from PTPs [9, 11-14]. Conversely, some researchers 83 84 have suggested that PTPs be contraindicated during the acute phase because the acute effects of the exercise 85 program may cause an increase in pro-inflammatory cytokines and viral replication [15, 16]. Nevertheless, a 86 recent study has shown an improvement in immune function after two weeks of moderate aerobic exercise,[17] 87 which is supported by previous review studies [18, 19]. Interestingly, most previous studies have investigated the 88 effects of PTPs in the acute phase or sub-acute phase in severe to critically ill patients with COVID-19 [11, 12, 89 14, 20, 21]. However, there are limited studies on the lesser severity of COVID-19 patients. Some of the 90 recommendations agreed that conventional PTPs and mild to moderate physical exercise can be applied to 91 COVID-19 patients with mild to moderate severity [13].

To our knowledge, bedside PTPs should be applied to patients as soon as and as often as possible. Some studies have discovered that more frequent bedside PTPs are more effective at lowering mortality rates, hospitalization days, and respiratory infections in ICU patients [22]. However, little is known about the effects of different bedside PTP frequencies in COVID-19 patients. Thus, this study aimed to compare the different bedside PTP frequencies on the survival rate, length of hospitalization (LoH), referrals to the ICU, and in-hospital complications. In addition, the safety of patients during and after performing PTPs was investigated. We hypothesized that COVID-

98 19 patients receiving daily bedside PTPs would have a significantly higher survival rate, lower LoH, as well as
99 fewer complications compared to those receiving fewer bedside PTPs. In addition, none of the COVID-19 patients
100 had serious adverse events during and after PTPs, and no physiotherapists tested positive for COVID-19 infection.

101 Methods

102 Study design

103 A prospective, quasi-experimental study design was used to determine the effects of PTPs in the acute phase of 104 patients with COVID-19. This study was conducted at Bamrasnaradura Infectious Diseases Institute, Nonthaburi 105 Province, Thailand, from November 2021 to January 2022. The technical approval was granted by the Human 106 Research Ethics Committee of the Bamrasnaradura Infectious Disease Institute, Nonthaburi Province (S020h/64), 107 and the Human Research Ethics Committee of Walailak University, Nakhon Si Thammarat Province (WU-EC-108 AL-3-186-64). Written informed consent was acquired from all participants. All procedures performed in this 109 study involving humans were in accordance with the ethical standards of the institutional and/or national research 110 committee and the 1964 Helsinki Declaration and its later amendment or comparable ethical standards.

111 Study population

112 Participants were assigned into two groups and stratified by age and gender. General inclusion criteria included 113 adults aged 18-65 years old with 1) a nucleic acid test-confirmed diagnosis of SAR CoV-2 infection, 2) 114 hospitalization due to any clinical signs and symptoms of pneumonia, 3) no communication problems, and 4) 115 ability to use an online mobile phone application. For specific inclusion criteria, patients were recruited if one of 116 the following criteria was indicated: [8, 9] 1) COVID-19 with risk factors for severe disease, 2) confirmed case 117 of pneumonia with hypoxia (resting blood oxygen saturation $(SpO_2) \le 96\%$ or the presence of exercise-induced 118 hypoxemia defined as a reduction in $SpO_2 > 3\%$ compared to baseline, 3) inability to expel secretions caused by 119 prolonged immobilization and respiratory muscle weakness, 4) presence of breathlessness or dyspnea needing 120 oxygen therapy (presence of signs of pneumonia with lung consolidation by chest radiograph or computerized 121 tomography or lung ultrasound), and 5) presence of functional limitation caused by prolonged hospitalization or 122 prolonged ICU stay or prolonged use of a respirator or oxygen device. Exclusion criteria included 1) unwillingness 123 or inability to follow the study protocol and 2) active participation in another study.

Characteristics and classification of disease severity of COVID-19 125

126 COVID-19 patients were categorized as mild, moderate, severe, and critical according to the World Health 127 Organization definition [23]. Mild severity (mild pneumonia) was defined as a person with the following 128 symptoms: fever, cough, fatigue, anorexia, shortness of breath, and myalgia. Moderate severity (moderate 129 pneumonia) was defined as a person with more pronounced signs and symptoms of viral pneumonia or hypoxia. 130 Severe COVID-19 was defined as a person with pneumonia accompanied by any signs and symptoms, including 131 respiratory rate > 30 times/min, and SpO₂ < 90% on room air. Critical disease was defined as a patient with ARDS 132 [23]. In addition, a laboratory investigation including the open reading frame gene1ab (ORF1ab) and the envelope 133 (E) gene of SARS-CoV-2, complete blood count (CBC), kidney and liver function, tissue damage markers (lactate 134 dehydrogenase (LDH)), inflammatory markers (i.e. erythrocyte sedimentation rate (ESR) and C-reactive protein 135 (CRP)), chest radiography, and medications were used to classify the severity of patients at baseline. A patient 136 who has been administered a combination of antiviral drugs and/or received corticosteroid treatment was classified 137 as a moderate to severe case.

Intervention (physiotherapy programs (PTPs) 138

139 Participants in Experimental Group One (Ex-G1) received only a one-time bedside PTPs for the first few days 140 after hospital admission. However, some patients remained confused of the program, and thus a second bedside 141 PTPs was taught to patients. Meanwhile, participants in Experimental Group Two (Ex-G2) had daily bedside 142 PTPs until hospital discharge. PTPs comprised of breathing exercises, secretion removal techniques (coughing, 143 huffing, and positioning), active chest trunk mobilization, active exercise of both limbs, and early progressive 144 mobilizations/ ambulation [9, 11-13]. The BreatheMax®V.2 device (C&D Biomedical, Thailand) that operates 145 based on a principle of positive expiratory pressure (PEP) and oscillating incentive spirometer (OIS) was given 146 to Ex-G2 patients. In addition, all patients were asked to join a closed private group via a mobile application 147 platform. Some of the patients were encouraged and monitored their signs and symptoms directly on their private 148 mobile application or ward phone, especially Ex-G1 participants who were taught only one-time PTPs.

149

Safety considerations for COVID-19 patients in assigning the 151

physiotherapy programs 152

153 Prior to perform bedside PTPs, all patient data, vital signs, and medical records were intensively reviewed by the 154 physiotherapists. Patients were questioned on their current signs and symptoms. Permission was not granted for 155 physiotherapist treatment if the patient had any of the following regardless of whether they were on a ventilator: 156 fraction of inspired oxygen (FiO₂) > 0.6, SpO₂ < 90%, respiratory rate (RR) > 40 times/min, positive end-157 expiratory pressure (PEEP) > 10 cmH₂O, ventilator resistance, unstable cardiovascular signs (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg, heart rate < 40 or > 120 beats/min) [24]. If SpO_2 158 159 decreased > 3% from baseline during the PTPs session, they were not allowed to continue the session.

Safety for physiotherapists to prevent SARS-CoV-2 transmission 160

Physiotherapists were trained to use personal protective equipment (PPE) properly before performing bedside 161 PTPs [9]. Importantly, all physiotherapists had to strictly follow aerosol, airborne, and contact precautions [9]. 162 163 For physiotherapist safety considerations, all of them must have 1) a minimum of two doses of the COVID-19 164 vaccine before initiation of the study for at least 2 weeks, 2) good health with no comorbidities, 3) age of < 45165 years [2], and 4) at least two years of experience in chest physiotherapy. All physiotherapists were tested weekly 166 for COVID-19 infection using reverse transcription-polymerase chain reaction (RT-PCR), and rapid antigen test 167 kit (ATK).

Outcome measures 168

169 The primary outcomes were survival rate, length of hospital stay (LoH), number of patients who were referred to 170 ICU, and rates/types of complications. The secondary outcome was the safety of the patients, which was indicated 171 by the minor and serious adverse events during and after each physical therapy session. A minor adverse event 172 was defined as an event that slightly affected the patient, requiring time for rest, and recovery within 15 minutes 173 for example; dizziness, nausea and vomiting, postural hypotension (blood pressure drop > 10 mmHg from 174 baseline), fatigue, and SpO₂ drop greater than 3% from baseline. A serious adverse event was defined as an event 175 that needed urgent assistance, for example, medications or resuscitation. In addition, the other secondary outcome 176 was the safety of the physiotherapists. The physiotherapists were tested for COVID-19 infection using RT-PCR 177 and ATK every week.

178 Laboratory tests

Blood samples were collected from all participants in the antebrachial area. RT-PCR was performed using a
Cobas® 6800 SARS-CoV-2 assay on the Cobas ® 6800 platforms (Roche Diagnostics, Basel, Switzerland) to
identify the presence of the ORF1ab and the E-gene of SARS-CoV-2. ATK was tested using a Singclean
(Hangzhou Singclean Medical Products, China). CBC was examined using an electrical impedance (Mindray
Model CAL 6000, China). Meanwhile, the renal function test, liver function test, and LDH were examined using
photometry (Beckman Coulter, USA). ESR was examined using the Westergren method (Mini-VES, Italy). CRP
was examined using immunofluorescence (UNICELL-S, China).

186 Statistical analysis

187 Descriptive data was reported as mean±SD or median (IQR) if it indicated normal or non-normal distribution of 188 data, respectively. The sample size was calculated using the G-Power program Version 3.10. The partial eta square (η^2) was set at a medium level. Assuming a moderate effect size of 0.25, a power of 90%, and a dropout rate of 189 190 20%, thus we planned for enrolling 52 participants. The parametric distribution was assessed using the Shapiro-191 Wilk test. Nominal data were summarized as frequencies and percentages. Categorical variables were compared 192 using the Chi-squared test or Fisher's exact test, as appropriate. Continuous variables were compared by 193 Independent t-test or Mann-Whitney U test, as appropriate. Data were analyzed using the Statistical Package for 194 Social Sciences Version 22.0 (IBM Inc., Armonk, NY). The level of significance was taken at 0.05 or 5%. 195

196 **Results**

197 Participant characteristics

Sixty-six COVID-19 patients were identified as eligible for participation. Fourteen participants were excluded as shown in Fig 1. Most participants were classified as having the Delta variant (one participant had the Omicron variant). The mean age of all participants was 45 ± 14 years, and 46% were men. Most participants (87%) were vaccinated against COVID-19. The COVID-19 severity was similar between groups (Table 1 and Table 2). Most participants (n = 49, 94%) were categorized as non-severe cases, which ranged from mild to moderate conditions of COVID-19. The proportions of disease severity were mild (n = 26; 50%), moderate (n = 23; 44%), and severe (n = 3; 6%) conditions. Most participants had comorbidities (n = 41, 79%). At the first bedside physiotherapy

205	visit, three Ex-G1 and twelve Ex-G2 patients were admitted to the intensive care unit (ICU). None of the baseline
206	characteristics were significantly different between groups (all $p > 0.05$) (Table 1 and Table 2). Most hematologic
207	parameters were in the normal range, except for the inflammatory markers of ESR and CRP (Table 2).
208	
209	Fig 1. Flow diagram for participants throughout this study
210	
211	
212	
213	
214	
215	
216	
217	
218	
219	
220	
221	
222	
223	
224	
225	
226	

	Ex-G1 $(n = 26)$	Ex-G2 $(n = 26)$	<i>P</i> Value
Men	12 (46%)	12 (46%)	1.000
Age, mean (SD), years	43.50 (13.34)	45.92 (15.24)	0.545
Age > 60 y	4 (16%)	5 (19%)	0.714
Education level			
Higher than bachelor degree	4 (16%)	1 (4%)	0.168
Bachelor degree	9 (35%)	7 (27%)	
Secondary school	4 (16%)	10 (38%)	
Primary school	7 (27%)	8 (31%)	
No formal education	2 (8%)	0	
On oxygen devices			
Nasal cannula	1 (4%)	3 (12%)	0.350
High flow nasal cannula	0	1 (4%)	
Mechanical ventilator	0	0	
Comorbidities			
No	4 (15%)	7 (27%)	0.308
Yes ^a	22 (85%)	19 (73%)	
BW, median (IQR), kg	69.50 (57.00, 89.25)	68.00 (57.00, 85.00)	0.905
BMI, median (IQR), kg/m ²	25.06 (22.83, 32.34)	26.88 (23.18, 30.99)	0.504
Classification of BMI ^b			
Obese	13 (50%)	16 (62%)	0.606
Overweight	6 (23%)	5 (19%)	
Normal	7 (27%)	5 (19%)	
COVID-19 disease severity			
Mild	15 (58%)	11 (42%)	0.538
Moderate	10 (38%)	13 (50%)	
Severe	1 (4%)	2 (8%)	
Duration from admission to initiating PT, mean	1.62 (0.80)	1.69 (1.09)	0.773
(SD), days			
Antiviral medication use			
Favipiravir	24 (92%)	22 (100%)	1.000
Mixed antiviral drug	13 (50%)	10 (40%)	0.402
Corticosteroid drug	3 (12%)	8 (32%)	0.090

Table 1. Comparison of baseline characteristics between groups.

Data expressed as n (%) unless otherwise stated.

^a Comorbidities included hypertension, diabetes mellitus, cerebrovascular accident, thyroid, allergy, glucose-6phosphate dehydrogenase deficiency, chronic hepatitis B infection, thalassemia, systemic lupus erythematosus, enlarged prostate, gout, old tuberculosis infection, migraine, and chronic kidney disease.

^b Obese = $BMI \ge 25$; overweight = $23 \le BMI < 25$; and normal = $18.5 \le BMI < 23$.
Abbreviation: BMI, body mass index; BW, body weight; COVID-19, Coronavirus Disease 2019; ICU
intensive care unit; IQR, interquartile range; PT, physiotherapy; SD, standard deviation

	Ex-G1 ($n = 26$)	Ex-G2 ($n = 25^{a}$)	P Value
ORF1ab gene, Ct	20.81 (17.76, 23.64)	20.56 (18.59, 24.10)	0.859
E-gene, Ct	21.70 (18.09, 24.09)	21.07 (19.03, 23.93)	0.861
Complete blood count			
WBC, mean (SD), $\times 10^{3}/uL$	6.90 (1.74)	7.01 (2.44)	0.856
RBC, mean (SD), 10 ⁶ /uL	5.07 (0.61)	4.83 (0.64)	0.167
HGB, mean (SD), g/dL	13.27 (1.56)	13.4 (1.45)	0.661
HCT, mean (SD), %	40.62 (4.44)	40.84 (4.01)	0.850
RDW, %	13.90 (13.00, 14.53)	13.50 (12.60, 13.90)	0.086
Platelet, $\times 10^{3}/\text{uL}$	254.00 (215.50, 293.75)	254.00 (207.50, 332.00)	0.706
Neutrophil, mean (SD), %	60.77 (13.39)	63.56 (12.94)	0.453
Lymphocyte, mean (SD), %	28.46 (12.34)	26.84 (12.83)	0.647
Monocyte, %	7.50 (6.00, 10.00)	6.00 (5.00, 9.50)	0.209
Eosinophil, %	1.00 (0.00, 3.00)	1.00 (0.00, 2.00)	0.486
Basophil, %	0.00 (0.00, 1.00)	0.00 (0.00, 1.00)	0.925
Kidney function test			
BUN, mg/dL	12.50 (9.00, 15.00)	11.00 (8.00, 17.00)	0.769
Creatinine, mg/dL	0.74 (0.64, 0.88)	0.71 (0.58, 1.04)	0.850
eGFR, mL/min/1.73m ²	106.01 (87.45, 115.83)	107.06 (71.72, 122.14)	0.880
eGFR stage, n (%)			
Stage I	19 (73%)	17 (68%)	0.086
Stage II	7 (27%)	4 (16%)	
Stage III	0	4 (16%)	
Liver function test			
Total protein, mean (SD), g/dl	7.74 (0.75)	7.63 (0.58)	0.655
Total bilirubin, mean (SD), mg/dl	0.49 (0.18)	0.52 (0.17)	0.855
Alkaline phosphate, U/L	69.00 (55.00, 88.00)	67.00 (52.00, 78.50)	0.516
AST/SGOT, U/L	26.00 (22.50, 36.50)	26.00 (23.00, 30.00)	0.437
ALT/SGPT, U/L	24.00 (17.00, 47.50)	22.00 (14.00, 39.00)	0.166
LDH, U/L	189.30 (159.50, 207.15)	176.30 (163.55, 242.85)	0.777
Inflammation biomarkers			
ESR, mean (SD), mm/hr	26.92 (13.06)	31.12 (19.00)	0.297
CRP, mg/dL	8.26 (3.56, 17.94)	13.89 (5.80, 25.66)	0.122

Table 2. Comparison of baseline blood biomarkers between groups.

Data expressed as median (IQR) unless otherwise stated.

a n = 25 due to a laboratory test of one participant that the clinician did not order.

Abbreviation: ALT/ SGPT, alanine aminotransferase/ serum glutamic-pyruvic transaminase; AST/ SGOT, aspartate aminotransferase/ serum glutamic-oxaloacetic transaminase; BUN, blood urine nitrogen; CRP, C-reactive protein; Ct, threshold cycle; E-gene, envelope gene; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; HCT, hematocrit; HGB, hemoglobin; LDH, lactate dehydrogenase; ORF1ab-gene, open reading frames ab gene; RBC, red blood cell; RDW, red blood cell distribution width; WBC, white blood cell

254			
255			
256			
257			
258			
259			
260			
261			
262			
263			
264			
265			
266			
267			
268			
269			
270			
271			

Ex-G2 (n = 26)Ex-G1 (n = 26)P Value 25 (96%) 1.000 Survival 26 (100%) 1 (4%) Death 0 1.000 10.00 (9.00, 11.80) 10.00 (10.00, 12.00) LoH, median (IQR), days 0.117 Patients referred to ICU 1 (4%) 0 0.313 Complications Influenza 0 0.555 1 (4%) Bacterial infection 2 (8%) 2 (8%) 0 1 (4%) Cardiac arrest None 24 (92%) 22 (84%) Minor adverse event 0 Drop of $SpO_2 > 3\%$ from baseline 8 (31%) 0.018 1 (4%) 1 (4%) Dizziness Nausea & vomiting 2 (8%) 0 ^a Dyspnea 2 (8%) 1 (4%) 0 ^a Dyspnea & drop of SpO₂ > 3% from baseline 1 (4%) None 21 (80%) 15 (57%) Average of PT bedside, median (IQR) 2.00 (1.00, 2.00) < 0.001 6.00 (5.00, 7.00) Number of patients receiving each PT program Breathing exercise, cough/ huff training, active 26 (100%) 26 (100%) 1.000 chest trunk mobilization, positioning, active exercise of UE and LE < 0.001 0 26 (100%) Positive expiratory pressure devices < 0.001 Out-of-bed exercise 0 26 (100%)

Table 3. Outcome measurement comparison between groups.

Data expressed as n (%) unless otherwise stated.

^a Dyspnea caused by continued cough during breathing exercise

Abbreviation: ICU; intensive care unit; IQR, interquartile range; LE, lower extremity; LoH, length of hospital stay; PT, physiotherapy; UE, upper extremity

272

278 **Primary outcomes**

- 279 There were no significant differences in all outcome measures found between the intervention groups (p > 0.05)
- 280 (Table 3). The survival rate of all COVID-19 patients was 98% in this study. The survival rate of COVID-19
- 281 patients with mild and moderate conditions was equal (100%) between the groups. There was only one Ex-G2
- 282 participant referred to the ICU room after enrollment to the study because of influenza. There were two Ex-G1
- and four Ex-G2 participants with complications after receiving PTPs (Table 3).

284 Secondary outcomes

Five Ex-G1 and eleven Ex-G2 COVID-19 patients had minor adverse events during and after the PTPs (Table 3). Among eight Ex-G2 participants, there were 14 sessions (9%) of the bedside PTPs that had a SpO₂ drop > 3% from baseline (Table 3). None of the participants had serious adverse events during and immediately after the PTPs. There was one Ex-G2 participant who died of cardiac arrest on the following day after the first bedside PTPs. There were no physiotherapists who tested positive for COVID-19 as a consequence of instructing bedside PTPs to patients. The number of physiotherapy sessions was significantly different between the groups (p < 0.001).

292

293 **Discussion**

294 To our knowledge, this is the first study to investigate the different frequencies of bedside PTPs in COVID-19 patients during admission to the hospital. In addition, there was a lack of study reports on the safety of bedside 295 296 PTPs in the acute phase of COVID-19 patients who were mostly identified with a mild to moderate degree of 297 severity. The main findings found no differences between groups in regard to survival rate, LoH, referrals to the 298 ICU, and in-hospital complications. Overall, there was a high survival rate of patients, no deaths among mild to 299 moderate COVID-19 patients, a limited number of COVID-19 patients who were referred to ICU after receiving the PTPs, and a low rate of complications observed after receiving the PTPs. Importantly, none of the serious 300 301 adverse events occurred during and immediately after each PTP session. In addition, no physiotherapists tested 302 positive for COVID-19 during two months of the in-hospital data collection period.

To date, there are few reports on the effects of PTPs documented in the acute phase of COVID-19 [<u>11</u>, <u>12</u>, <u>14</u>]. In literature, most previous studies have investigated physical rehabilitation in severe cases of COVID-19 or

in patients who were referred to ICU[<u>11</u>, <u>14</u>] or after recovery from critical illnesses [<u>20</u>, <u>21</u>]. Also, a study assessed patients who were negative for SAR-CoV-2 by laboratory diagnostic tests [<u>21</u>] or long-lasting hospital stay, which was safer and less likely to be infected with COVID-19 compared to our study conducted with active COVID-19. Interestingly, previous studies have reported that PTPs were safe and feasible in the ICU setting or the post-recovery period [<u>14</u>, <u>20</u>, <u>21</u>]. PTPs also improved the patient's motor and respiratory function, along with functional activity, particularly in post-critical illness patients [<u>14</u>, <u>20</u>, <u>21</u>]. However, those patients were older and had more severe conditions than patients in the present study [<u>11</u>, <u>12</u>, <u>14</u>].

312 The effects of PTPs in the current study may provide positive effects on physical function similar to a previous study that had examined a one-week telerehabilitation in mild to moderate COVID-19 patients who were confined 313 314 at home [25]. To support this, there was only one patient who was referred to the ICU, few complications found, 315 and none of the patients with mild to moderate conditions died in the present study. In addition, our study showed 316 minor complications (9.6%, 4 bacterial infections, 1 influenza) compared to an earlier study that had found 317 approximately 39% of complications in patients aged between 19 and 49 years [26]. Also, there were no patients 318 who developed ARDS in this study, which is contrary to a previous study that had reported 23% and 4% of ARDS 319 in the pneumonia group and mild to moderate group, respectively [27]. For these reasons, the survival rate of 320 patients with mild to moderate conditions in the current study was very high, contrary to many previous studies 321 [12, 14]. Meanwhile, the LoH of a previous study [20] is comparable to the present study, which was 9.8 days. 322 Similarly, the median LoH of patients with pneumonia not caused by COVID-19 was 9 days [28]. In contrast, a 323 recent review study had found that the median LoH of COVID-19 patients in China and other countries was 14 324 and 5 days, respectively. However, the LoH during the first year of the COVID-19 pandemic showed higher LoH 325 compared to the current study [29]. The variations in LoH could be due to differences in health policies for each 326 country, the development of treatment, and the effectiveness of vaccination. In Thailand, the Ministry of Public 327 Health has announced that COVID-19 patients must stay in the hospital for at least 10 days as a control against 328 SAR-CoV-2 transmission.

The two most used PTPs including breathing exercises and progressive mobilization/ exercise confirmed that they were safe for COVID-19 patients. None of the patients experienced serious adverse events during and immediately after the PTPs. This might be caused by the comprehensive screening of patients' clinical records before and after the PTPs [20]. Among the minor adverse events, a drop of $SpO_2 > 3\%$ from baseline was the most common adverse effect found in the Ex-G2 group because participants in the Ex-G2 group were encouraged at

334 the bedside to perform light exercise/ ambulation. Our findings support a recent systemic review that had found 335 that pulmonary rehabilitation was safe and feasible for COVID-19 patients [30]. In addition, it is in line with a 336 previous recommendation that patients with mild conditions may benefit from breathing exercises [31]. A 337 previous study has also shown symptomatic improvement after six weeks of an online breathing program for 338 patients with post-COVID-19 condition [32]. In addition, patients with mild symptoms of SARS-CoV-2 were 339 able to perform mild-to-moderate intensity exercise during active COVID-19 [33]. However, the exercise intensity 340 which is higher than the lactate threshold might not be appropriate according to the production of the respiratory 341 droplet [34]. Also, previous studies have demonstrated that exercise at moderate intensity could downregulate 342 inflammatory cytokines and stimulate the release of anti-inflammatory substances [18, 19]. Likewise, two weeks 343 of moderate aerobic exercise for COVID-19 patients recently have shown an improvement in immune function 344 [17]. A recent study supported that exercise promotes myokines production which would alleviate SARS-CoV-2 345 infectivity [35]. Besides the physical aspect, the psychological impact may also improve after bedside PTPs which 346 is supported by a previous study [36]. The PTPs in this study are similar to our study, except for craft activities, 347 which were added in the previous study [36]. Thus, a positive immune system response, the release of anti-SAR 348 CoV-2 substances, and mental improvement after the PTPs might promote the beneficial effects on most of the 349 primary outcome measures. Notably, we provided the BreatheMax, a breathing biofeedback device, to Ex-G2 350 patients. From our observation, it can increase SpO_2 within a few minutes, similar to a conventional breathing 351 exercise. Thus, this study supports a previous recommendation that PEP or OIS devices can be applied to COVID-352 19 patients without complications [9]. Interestingly, one to two times of bedside PTPs provided equal benefits 353 compared to the daily PTP group. This may be caused by the patients of both groups being encouraged to perform 354 PTPs via a ward phone, private mobile phone application, and closed private groups. Thus, daily bedside PTPs 355 may be unnecessary to implement for COVID-19 patients with mild to moderate conditions. Telemedicine is an 356 alternative platform in the case of restrictions for bedside PTPs. Importantly, our study confirmed that bedside 357 PTPs were safe for physiotherapists because there were no reports of COVID-19 infection during the two months 358 of prospective data collection among these physiotherapists. Indeed, the physiotherapists in our study strictly 359 followed the airborne, aerosol, and manual contact precautions when providing bedside PTPs to reduce the 360 possibility of SARS-CoV-2 infection.

There were some limitations in the present study. First, this study did not have a control group, and thus there were no data to compare with conventional treatment. Second, the objective outcome measures and psychological status at baseline could not be performed due to unstable signs and symptoms and concerns about COVID-19

transmission, which were similar to most previous case reports that were unable to perform those tests [11, 12]. In addition, blood biomarkers and chest radiographs were not allowed to be tested before discharge according to the limitation of hospital rules. These variables may have been useful to explain the physiological changes after the PTPs. Third, according to the quarantine rule, patients could not be discharged from the hospital even if there were no complications and they had almost fully recovered from COVID-19 infection. Consequently, the LoH among the groups found no differences. Future studies are highly recommended to confirm the findings of the present study with a conventional treatment control group and regardless of a mandatory quarantine rule.

371 Conclusion

372 The different bedside PTP frequency in COVID-19 patients with primarily mild to moderate conditions found no

373 differences in the survival rate, LoH, referrals to the ICU, and in-hospital complications. PTPs are safe for

374 COVID-19 patients and physiotherapists. A prudent assessment and monitoring of physiological parameters

375 during the PTPs are necessary to prevent unpredictable adverse events.

Supporting information

- 377 S1 raw data
- 378 (XLSX)
- 379 S2 Trend checklist
- **380** (PDF)

381 Acknowledgments

We would like to thank all the researchers who participated in this study, in particular, the physiotherapists involved in the data collection processes. They were willing to join the study even though they might have a chance to contract COVID-19. The authors are thankful to the Bamrasnaradura Infectious Disease Institute, which allowed us to collect data. Importantly, we are indebted to all COVID-19 patients, who devoted time to participate in this study.

387 Author Contributions

388 Conceptualization: Khomkrip Longlalerng, Netchanok Jianramas, Veeranoot Nissapatorn, Chaisith Sivakorn,
389 Maria de Lourdes Pereira, Chenpak Salesingh, Eittipad Jaiyen.

- **390** Data curation: Khomkrip Longlalerng, Netchanok Jianramas, Anuttra (Chaovavanich) Ratnarathon, Chenpak
- 391 Salesingh, Eittipad Jaiyen, Salinee Chaiyakul, Nitita Piya-amornphan, Thanaporn Semphuet, Thanrada
- **392** Thiangtham, Kornchanok Boontam.
- 393 Formal analysis: Khomkrip Longlalerng, Netchanok Jianramas.
- 394 Funding acquisition: Khomkrip Longlalerng, Maria de Lourdes Pereira.
- 395 Investigation: Khomkrip Longlalerng, Netchanok Jianramas, Anuttra (Chaovavanich) Ratnarathon, Chenpak
- 396 Salesingh, Eittipad Jaiyen, Salinee Chaiyakul, Nitita Piya-amornphan, Thanaporn Semphuet, Thanrada
- **397** Thiangtham, Kornchanok Boontam.
- 398 Methodology: Khomkrip Longlalerng, Netchanok Jianramas, Veeranoot Nissapatorn, Chaisith Sivakorn, Maria
- 399 de Lourdes Pereira, Anuttra (Chaovavanich) Ratnarathon, Chenpak Salesingh, Eittipad Jaiyen, Salinee Chaiyakul,
- 400 Nitita Piya-amornphan, Thanaporn Semphuet, Thanrada Thiangtham.
- 401 Project administration: Khomkrip Longlalerng, Netchanok Jianramas.
- 402 Writing original draft: Khomkrip Longlalerng.
- 403 Writing review & editing: Khomkrip Longlalerng, Netchanok Jianramas, Veeranoot Nissapatorn, Chaisith
- 404 Sivakorn, Maria de Lourdes Pereira, Anuttra (Chaovavanich) Ratnarathon, Chenpak Salesingh, Eittipad Jaiyen,
- 405 Salinee Chaiyakul, Nitita Piya-amornphan, Thanaporn Semphuet, Thanrada Thiangtham, Kornchanok Boontam.
- 406

407

408

- 410
- 411
- 412

413 **References**

- World Health Organization. Coronavirus disease (COVID-19) pandemic. 2022 [Available from:
 https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
- 416 2. Department of disease control of Thailand. Covid-19 infected situation updated daily. 2022 [Available
 417 from: https://ddc.moph.go.th/viralpneumonia/index.php.
- 418 3. da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, Farias de Oliveira T, Campos
 419 Alcântara R, Monteiro Arnozo G, et al. Clinical manifestations of COVID-19 in the general population:
- 420 systematic review. Wien Klin Wochenschr. 2021;133(7-8):377-82.
- 421 4. Ochani R, Asad A, Yasmin F, Shaikh S, Khalid H, Batra S, et al. COVID-19 pandemic: from origins to
 422 outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation,
 423 and management. Infez Med. 2021;29(1):20-36.
- Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, et al. The prevalence of
 symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic
 review and meta-analysis of 148 studies from 9 countries. PLOS ONE. 2020;15(6):e0234765.
- 427 6. He X, Cheng X, Feng X, Wan H, Chen S, Xiong M. Clinical symptom differences between mild and
 428 severe COVID-19 patients in China: A meta-analysis. Front Public Health. 2021;8(954).
- van der Lee L, Hill AM, Jacques A, Patman S. Efficacy of respiratory physiotherapy interventions for
 intubated and mechanically ventilated adults with pneumonia: a systematic review and meta-analysis.
 Physiother Can. 2021;73(1):6-18.
- Felten-Barentsz KM, van Oorsouw R, Klooster E, Koenders N, Driehuis F, Hulzebos EHJ, et al.
 Recommendations for hospital-based physical therapists managing patients with COVID-19. Phys Ther.
 2020;100(9):1444-57.
- 435 9. Thomas P, Baldwin C, Beach L, Bissett B, Boden I, Cruz SM, et al. Physiotherapy management for
 436 COVID-19 in the acute hospital setting and beyond: an update to clinical practice recommendations. J
 437 Physiother. 2022;68(1):8-25.
- Vitacca M, Carone M, Clini EM, Paneroni M, Lazzeri M, Lanza A, et al. Joint statement on the role of
 respiratory rehabilitation in the COVID-19 crisis: the Italian position paper. Respiration. 2020;99(6):4939.

- 441 11. Eggmann S, Kindler A, Perren A, Ott N, Johannes F, Vollenweider R, et al. Early physical therapist
 442 interventions for patients with COVID-19 in the acute care hospital: A case report series. Phys Ther.
 443 2021;101(1).
- Gaspari CH, Assumpção I, Freire R, Silva A, Santiso C, Jaccoud AC. The first 60 days: physical therapy
 in a neurosurgical center converted into a COVID-19 center in Brazil. Phys Ther. 2020;100(12):2120-6.
- Wittmer VL, Paro FM, Duarte H, Capellini VK, Barbalho-Moulim MC. Early mobilization and physical
 exercise in patients with COVID-19: A narrative literature review. Complement Ther Clin Pract.
 2021:43:101364.
- Li L, Yu P, Yang M, Xie W, Huang L, He C, et al. Physical therapist management of COVID-19 in the
 intensive care unit: the west China hospital experience. Phys Ther. 2021;101(1).
- 451 15. Kiel RJ, Smith FE, Chason J, Khatib R, Reyes MP. Coxsackievirus B3 myocarditis in C3H/HeJ mice:
 452 description of an inbred model and the effect of exercise on virulence. Eur J Epidemiol. 1989;5(3):348453 50.
- Lazzeri M, Lanza A, Bellini R, Bellofiore A, Cecchetto S, Colombo A, et al. Respiratory physiotherapy
 in patients with COVID-19 infection in acute setting: a position paper of the Italian Association of
 Respiratory Physiotherapists (ARIR). Monaldi Arch Chest Dis. 2020;90(1).
- 457 17. Mohamed AA, Alawna M. The effect of aerobic exercise on immune biomarkers and symptoms severity
 458 and progression in patients with COVID-19: A randomized control trial. J Bodyw Mov Ther.
 459 2021;28:425-32.
- 460 18. Martin SA, Pence BD, Woods JA. Exercise and respiratory tract viral infections. Exerc Sport Sci Rev.
 461 2009;37(4):157-64.
- 462 19. Leandro CG, Ferreira E Silva WT, Lima-Silva AE. Covid-19 and exercise-induced immunomodulation.
 463 Neuroimmunomodulation. 2020;27(1):75-8.
- Piquet V, Luczak C, Seiler F, Monaury J, Martini A, Ward AB, et al. Do patients with COVID-19 benefit
 from rehabilitation? functional outcomes of the first 100 patients in a COVID-19 rehabilitation unit. Arch
 Phys Med Rehabil. 2021;102(6):1067-74.
- Zampogna E, Paneroni M, Belli S, Aliani M, Gandolfo A, Visca D, et al. Pulmonary rehabilitation in
 patients recovering from COVID-19. Respiration. 2021;100(5):416-22.

- 22. Castro AAM, Calil SR, Freitas SA, Oliveira AB, Porto EF. Chest physiotherapy effectiveness to reduce
 hospitalization and mechanical ventilation length of stay, pulmonary infection rate and mortality in ICU
 patients. Respir Med. 2013;107(1):68-74.
- World Health Organization. Living guidance for clinical management of COVID-19: Living guidance,
 23 November 2021. 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-
- 474 clinical-2021-2.
- 475 24. Abdullahi A. Safety and efficacy of chest physiotherapy in patients with COVID-19: a critical review.
 476 Front Med (Lausanne). 2020;7(454).
- 477 25. Gonzalez-Gerez JJ, Saavedra-Hernandez M, Anarte-Lazo E, Bernal-Utrera C, Perez-Ale M, Rodriguez478 Blanco C. Short-Term effects of a respiratory telerehabilitation program in confined COVID-19 patients
- in the acute phase: A pilot study. Int J Environ Res Public Health. 2021;18(14).
- 26. Drake TM, Riad AM, Fairfield CJ, Egan C, Knight SR, Pius R, et al. Characterisation of in-hospital
 complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol
 UK: a prospective, multicentre cohort study. The Lancet. 2021;398(10296):223-37.
- 483 27. Minh LHN, Abozaid AA-F, Ha NX, Le Quang L, Gad AG, Tiwari R, et al. Clinical and laboratory factors
 484 associated with coronavirus disease 2019 (Covid-19): A systematic review and meta-analysis. Rev Med
 485 Virol. 2021;31(6):e2288.
- 486 28. Menéndez R, Cremades MJ, Martínez-Moragón E, Soler JJ, Reyes S, Perpiñá M. Duration of length of
 487 stay in pneumonia: influence of clinical factors and hospital type. Eur Respir J. 2003;22(4):643.
- 488 29. Hartsgrove C, Guevarra-Fernandez J, Kendall J, Delauter G, Kirshblum S. Measuring Discharge
 489 Outcomes, Length of Stay, and Functional ADL Score During COVID-19 in Inpatient Rehabilitation
 490 Hospitals. Arch Phys Med Rehabil. 2021;102(12):2291-9.
- 491 30. Ahmed I, Mustafaoglu R, Yeldan I, Yasaci Z, Erhan B. Effect of pulmonary rehabilitation approaches
 492 on dyspnea, exercise capacity, fatigue, lung functions and quality of life in patients with COVID-19: A
 493 Systematic Review and Meta-Analysis. Arch Phys Med Rehabil. 2022;103(10):2051-62.
- 494 31. Righetti RF, Onoue MA, Politi FVA, Teixeira DT, Souza PN, Kondo CS, et al. Physiotherapy care of
 495 patients with Coronavirus Disease 2019 (COVID-19) A Brazilian experience. Clinics (Sao Paulo).
 496 2020;75:e2017.

- 497 32. Philip KEJ, Owles H, McVey S, Pagnuco T, Bruce K, Brunjes H, et al. An online breathing and wellbeing
 498 programme (ENO Breathe) for people with persistent symptoms following COVID-19: a parallel-group,
- 499 single-blind, randomised controlled trial. Lancet Respir Med. 2022;10(9):851-63.
- 33. Zhu Y, Wang Z, Zhou Y, Onoda K, Maruyama H, Hu C, et al. Summary of respiratory rehabilitation and
 physical therapy guidelines for patients with COVID-19 based on recommendations of World
 Confederation for Physical Therapy and National Association of Physical Therapy. J Phys Ther Sci.
 2020;32(8):545-9.
- 504 34. Katsumata Y, Sano M, Okawara H, Sawada T, Nakashima D, Ichihara G, et al. Laminar flow ventilation
 505 system to prevent airborne infection during exercise in the COVID-19 crisis: A single-center
 506 observational study. PLOS ONE. 2021;16(11):e0257549.
- 507 35. Bhardwaj V, Dela Cruz M, Subramanyam D, Kumar R, Markan S, Parker B, et al. Exercise-induced
 508 myokines downregulates the ACE2 level in bronchial epithelial cells: Implications for SARS-CoV-2
 509 prevention. PLOS ONE. 2022;17(7):e0271303.
- 510 36. Jung JH, Won JJ, Ko JY. Psychological rehabilitation for isolated patients with COVID-19 infection: A
 511 randomized controlled study. PLOS ONE. 2022;17(12):e0278475.
- 512